Annual General Meeting of Active Biotech AB
18 May 2018 - 4:30PM
PRESS RELEASE
The Annual
General Meeting of Active Biotech was held on May 17, 2018.
In accordance with the Board of Directors'
proposal, it was resolved that no dividend would be paid.
The board members and the managing director were
discharged from liability with respect to their management of the
company for 2017.
In accordance with the Election
Committee's proposal, the Board members Mats Arnhög,
Magnhild Sandberg-Wollheim, Peter Sjöstrand and Peter Thelin were
re-elected. The Meeting also resolved to
re-elect Mats Arnhög as Chairman of the Board. KPMG AB was
re-elected as auditor.
Furthermore, in accordance with the Election
Committee's proposal, the Meeting resolved that the Election
Committee shall be composed of representatives for the three
largest owners, as per the end of September, 2018, as well as the
Chairman of the Board.
The Meeting approved the Board's proposal
concerning guidelines for remuneration to the President and other
senior executives. The guidelines essentially conform to the
principles applied to date.
In accordance with the Board's proposal, the
Meeting resolved to authorize the Board, for a period that does not
extend past the date of the next Annual General Meeting, to resolve
on the issue of not more than 14 million new shares and/or
convertibles with the corresponding dilution effect, with or
without pre-emptive rights for the company's shareholders.
Lund, May 18, 2018
Active Biotech AB (publ)
Helén Tuvesson
President and CEO
For further information, please
contact:
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB (publ)
(NASDAQ Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties is in development for neurodegenerative diseases in
partnership with Teva Pharmaceutical Industries Ltd. ANYARA, an
immunotherapy, in development for cancer indications in partnership
with NeoTX Therapeutics Ltd. Furthermore, commercial activities are
conducted for the tasquinimod, paquinimod and SILC projects. Please
visit http://www.activebiotech.com/en for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Annual General Meeting of Active
Biotech AB
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Nov 2023 to Nov 2024